Hantz Financial Services, Inc. Biomarin Pharmaceutical Inc Transaction History

Hantz Financial Services, Inc.

$6.6 Billion
Q3 2025

A detailed history of Hantz Financial Services, Inc. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Hantz Financial Services, Inc. holds 1,555 shares of BMRN stock, worth $85,105. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,555

Previous 1,056 47.25%

Holding current value

$85,105

Previous $58,000 44.83%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 04, 2025	BUY	$52.62 - $61.93 $26,257 - $30,903	499 Added 47.25%	1,555 $84,000
Q2 2025 Aug 04, 2025	BUY	$54.08 - $68.32 $47,265 - $59,711	874 Added 480.22%	1,056 $58,000
Q1 2025 May 12, 2025	BUY	$61.25 - $72.83 $3,736 - $4,442	61 Added 50.41%	182 $13,000
Q3 2024 Nov 13, 2024	BUY	$69.02 - $93.84 $2,967 - $4,035	43 Added 55.13%	121 $9,000
Q2 2024 Jul 30, 2024	BUY	$74.43 - $92.22 $5,805 - $7,193	78 New	78 $6,000

Q1 2024 Aug 06, 2024	SELL	$83.81 - $99.0 $1,005 - $1,188	-12 Reduced 13.33%	78 $7,000
Q2 2023 Aug 06, 2024	SELL	$86.68 - $100.3 $4,594 - $5,315	-53 Reduced 37.06%	90 $8,000
Q4 2022 Aug 06, 2024	SELL	$80.93 - $108.63 $3,318 - $4,453	-41 Reduced 22.28%	143 $15,000
Q3 2022 Aug 06, 2024	SELL	$82.16 - $96.94 $246 - $290	-3 Reduced 1.6%	184 $16,000
Q2 2022 Aug 06, 2024	SELL	$71.48 - $86.85 $2,072 - $2,518	-29 Reduced 13.43%	187 $15,000
Q1 2022 Aug 06, 2024	SELL	$74.28 - $92.69 $805,566 - $1.01 Million	-10,845 Reduced 98.05%	216 $17,000
Q4 2021 Aug 06, 2024	BUY	$71.72 - $91.47 $56,013 - $71,438	781 Added 7.6%	11,061 $977,000
Q3 2021 Aug 06, 2024	BUY	$74.77 - $85.47 $177,877 - $203,333	2,379 Added 30.11%	10,280 $795,000
Q2 2021 Aug 06, 2024	BUY	$75.51 - $84.79 $32,997 - $37,053	437 Added 5.85%	7,901 $659,000
Q1 2021 Aug 06, 2024	BUY	$74.73 - $90.69 $551,955 - $669,836	7,386 Added 9469.23%	7,464 $564,000
Q4 2020 Aug 06, 2024	BUY	$72.61 - $90.2 $8,350 - $10,373	115 Added 1.46%	7,973 $699,000
Q3 2020 Aug 06, 2024	BUY	$71.87 - $131.03 $52,608 - $95,913	732 Added 10.27%	7,858 $598,000
Q2 2020 Aug 06, 2024	SELL	$79.55 - $124.22 $9,784 - $15,279	-123 Reduced 1.7%	7,126 $879,000
Q1 2020 Aug 06, 2024	BUY	$71.37 - $96.85 $511,794 - $694,511	7,171 Added 9193.59%	7,249 $613,000

Others Institutions Holding BMRN

# of Institutions

667

Shares Held

182M

Call Options Held

1.48M

Put Options Held

957K

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $10.2B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hantz Financial Services, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Hantz Financial Services, Inc. with notifications on news.

Account

Hantz Financial Services, Inc. Biomarin Pharmaceutical Inc Transaction History